Study: Teprotumumab improves symptoms of TED
Results from a recent study using teprotumumab in the treatment of thyroid eye disease (TED) support previously reported improvements in proptosis and clinical activity score (CAS) and suggest the drug also may improve light sensitivity, IOP, motility deficit, dry eyes, and periorbital edema, according to a poster presented at ARVO 2021.
The retrospective cohort study evaluated additional efficacy parameters in patients receiving teprotumumab in the Expanded Access Program, which started prior to the drug’s approval in January of 2020 for the treatment of TED. Study participants included adults with a clinical diagnosis of active, moderate-to-severe TED with a CAS equal to or greater than 4 with onset of TED within 12 months. Patients were provided 8 infusions (10 mg/kg first infusion, 20 mg/kg thereafter) every 3 weeks over 21 weeks.
The analysis included 13 patients with an average age of 46.5 years with a mean TED duration of 7.1 months. Overall, 77% received the complete set of 8 infusions (3 discontinued). At week 21, the change from baseline was -4.6 mm for proptosis and -4.0 for CAS, -9.1 for light sensitivity, and -3.6 mmHg for IOP. Six patients had abnormal wetting test at eligibility visit, compared to 3 at week 21; 6 patients had manifest strabismus, 5 of whom had complete data. Of the 5 patients, 4 patient had improvements in either extraocular motility or strabismus measurements. Facial volumetric analysis demonstrated reductions in both upper and lower lid volume.
Wang Y, et al. Teprotumumab for the treatment of thyroid eye disease: clinical experience from Expanded Access Program (EAP). Presented at: ARVO 2021.